Quantcast

Got Stocks from QualityStocks Ones To Watch

Got Stocks

Find out which Small-Cap / Micro-Caps should be on your radar. Get the news and information that moves the markets this week and the "Ones to Watch", only at QualityStocks. The "Quality" is Back in Stocks...




Untitled Document

Immune Therapeutics, Inc. (IMUN)

Immune Therapeutics, Inc. is a biotechnology company whose shares trade on the OTC Markets' Group's OTCQB. It is working to combat chronic, life-threatening diseases via the activation and modulation of the body's immune system using its patented immunotherapy. The company's proprietary technology, therapies, as well as patents include the treatment of a broad spectrum of cancers. Immune Therapeutics has its corporate headquarters in Orlando, Florida.

The company's most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes called opioid growth factor) and its Low Dose Naltrexone product (LDN) or Lodonal™. These have been shown to stimulate the immune system even in patients with advanced cancer. The design of Immune Therapeutics' products and immunotherapy technologies are to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Airmed Biopharma Limited is the company's Irish subsidiary. It is its pharmaceutical sales division. Airmed Biopharma is responsible for servicing sales orders for Lodonal™ in countries where Immune Therapeutics has received sales approval in Latin America and Africa.

TNI BioTech International, Ltd., a BVI company is Immune Therapeutics' subsidiary. TNI BioTech International is responsible for managing the company's global distribution.

Management will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of autoimmune states including rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of an assortment of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.

Recently, Immune Therapeutics announced that an agreement between Immune Therapeutics GB Pharma/AHAR with Fidson Healthcare will enable Fidson marketing, sales, customer support, and technical assistance organization to promote Lodonal™ in Nigeria. This will raise the Immune Therapeutics and GB Pharma/AHAR distribution network to the next level. The distribution will become effective upon completion of the continuing NAFDAC approved 90-day Bridging trial evaluating the efficacy and safety of Lodonal™.

Immune Therapeutics in partnership with GB Pharma Holdings Inc. and American Hospitals & Resort [AHAR] have signed a Letter of Intent (LOI) with Nigerian public company, Fidson Healthcare Plc. Fidson is one of Nigeria's foremost pharmaceutical companies. TNI BioTech International is the contracting entity with the Nigerian 90-Day Bridging trial.

GB Pharma Holdings is a Washington D.C. international Pharmaceutical company. It has expertise in defining policies, facilitating approvals, distribution and cGMP (current Good Manufacturing Practices) and introducing inventive therapies to Africa.

 

 

 

The QualityStocks
Newsroom

Read the articles covering the biggest movers in the markets today.

Continue

Market
Basics

Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.

Continue

The QualityStocks Daily
Archives

Go back to see our previous newsletters and find out what you might have missed.

Continue